title: Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.
abstract: Primary cutaneous lymphomas are a heterogeneous group of diseases. They often remain localized, and they generally have a more indolent course and a better prognosis than lymphomas in other locations. They are highly radiosensitive, and radiation therapy is an important part of the treatment, either as the sole treatment or as part of a multimodality approach. Radiation therapy of primary cutaneous lymphomas requires the use of special techniques that form the focus of these guidelines. The International Lymphoma Radiation Oncology Group has developed these guidelines after multinational meetings and analysis of available evidence. The guidelines represent an agreed consensus view of the International Lymphoma Radiation Oncology Group steering committee on the use of radiation therapy in primary cutaneous lymphomas in the modern era.
authors: Departments of Oncology and Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address: lena.specht@regionh.dk.
authors: Lena
authors: L
authors: Specht
authors: Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Bouthaina
authors: B
authors: Dabaja
authors: Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Sciences Centre, The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
authors: Tim
authors: T
authors: Illidge
authors: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut.
authors: Lynn D
authors: LD
authors: Wilson
authors: Department of Radiation Oncology, Stanford University, Stanford, California.
authors: Richard T
authors: RT
authors: Hoppe
mesh_terms: D032921:Consensus; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000532:radiotherapy*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000473:pathology / Q000532:radiotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology / Q000532:radiotherapy; D017728:Lymphoma, Large-Cell, Anaplastic / Q000473:pathology / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000532:radiotherapy; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology / Q000532:radiotherapy*; D009182:Mycosis Fungoides / Q000473:pathology / Q000532:radiotherapy; D056888:Patient Positioning; D011379:Prognosis; D011836:Radiation Tolerance; D011879:Radiotherapy Dosage; D012878:Skin Neoplasms / Q000473:pathology / Q000532:radiotherapy*